文献速递妇科

影像引导近距离放疗作为不可手术子宫内膜癌患者非手术治疗组成部分的实施

Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients.
PubMed 文献 · Gynecol Oncol · 2020-05-29

本研究回顾性纳入27例不可手术子宫内膜癌患者,评估外照射放疗(45Gy)后行3D影像引导近距离放疗的疗效;5年总生存率为63%(95%CI=43-91),局部、盆腔和远处失败累积发生率分别为19%、7%和26%,晚期≥2级泌尿和胃肠毒性分别为15%和7%。

要点

  • 外照射45Gy后行3D影像引导近距离放疗,CTVBT中位D90为60.7 GyEQD2(IQR=56.4-64.2)。
  • 5年总生存率63%(95%CI=43-91),局部失败累积发生率19%(n=5)。
  • 晚期≥2级泌尿毒性和胃肠毒性分别为4例(15%)和2例(7%),无≥2级阴道毒性。

核心结论

  • 外照射放疗后行腔内近距离放疗似乎是不可手术子宫内膜癌的有效选择。
  • 近距离放疗时实施3D概念可能有助于提高局部控制概率并降低毒性。
  • 需要大规模回顾性或前瞻性数据来证实这些早期数据。

研究设计与样本

  • 回顾性纳入所有连续接受外照射放疗后行3D影像引导近距离放疗的不可手术子宫内膜癌患者,共27例。
  • 外照射放疗剂量为45Gy,随后行3D影像引导的子宫阴道近距离放疗。
  • 近距离放疗临床靶体积(CTVBT)包括整个子宫和初始病变范围,大体肿瘤体积(GTVres)包括近距离放疗时的残留病变。

主要发现

  • 包括外照射和近距离放疗,CTVBT的中位D90为60.7 GyEQD2(IQR=56.4-64.2),GTVres的中位D90为73.6 GyEQD2(IQR=64.1-83.7)。
  • 中位总治疗时间为50天(IQR=46-54),平均随访36.5个月(SD=30.2)。
  • 局部、盆腔和远处失败累积发生率分别为19%(n=5)、7%(n=2)和26%(n=7)。
  • 5年总生存率为63%(95%CI=43-91)。
  • 晚期≥2级泌尿毒性和胃肠毒性分别见于4例(15%)和2例(7%),未报告≥2级阴道毒性。

局限性

  • 原文为回顾性研究。
  • 样本量为27例。
  • 作者指出需要大规模回顾性或前瞻性数据来证实这些早期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed outcomes of inoperable endometrial cancer (IEC) patients treated with definitive external beam radiation therapy (EBRT) followed by a 3D image-guided brachytherapy boost. METHODS: All consecutive patients treated with EBRT followed by 3D image-guided brachytherapy for IEC were retrospectively included. EBRT delivered a dose of 45Gy. Then, patients had an uterovaginal brachytherapy guided by 3D imaging. Clinical target volume (CTVBT) included the whole uterus and the initial disease extent. Gross tumour volume (GTVres) included the residual disease at time of brachytherapy. RESULTS: Twenty-seven patients were identified. Causes of inoperability were comorbidities (37%) or tumour loco regional extent (63%). Including EBRT and brachytherapy, the median D90 (minimal dose delivered to 90% of the volume) was 60.7 GyEQD2 (IQR = 56.4-64.2) for the CTVBT, and was 73.6 GyEQD2 (IQR = 64.1-83.7) for the GTVres. The median overall treatment time was 50 days (IQR = 46-54). The mean follow-up was 36.5 months (SD = 30.2). The cumulative incidence of local, pelvic and distant failures was 19% (n = 5), 7% (n = 2) and 26% (n = 7), respectively. Five-year overall survival was 63% (95% CI = 43-91). Late urinary and gastro intestinal toxicities ≥ grade 2 were reported in four (15%) and two patients (7%) respectively. No vaginal toxicity ≥ grade 2 was reported. CONCLUSIONS: EBRT followed by intracavitary brachytherapy seems to be an effective option for IEC. The implementation of 3D concepts at time of brachytherapy may contribute to high local control probability and low toxicity profile. Large scale retrospective or prospective data are needed to confirm these early data.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Espenel S, Kissel M, Garcia MA, et al. Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients. Gynecol Oncol. 2020. PMID: 32475773. doi:10.1016/j.ygyno.2020.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。